Keyphrases
Genetic Variants
100%
Randomized Placebo-controlled Trial
100%
Smokers
100%
Nicotinic Receptors
100%
Nicotine Replacement Therapy
100%
Varenicline
100%
Cholinergic Receptors
100%
Genotype
83%
Smoking Cessation Intervention
66%
Placebo
50%
European Ancestry
50%
Treatment Interaction
33%
African American Smokers
33%
Treatment Response
16%
Trial Registration
16%
Counseling
16%
Response Predictors
16%
Missouri
16%
St. Louis
16%
Treatment Efficacy
16%
6-month Follow-up
16%
Genetic Analysis
16%
Non-Europeans
16%
Abstinence
16%
Rs16969968
16%
End of Treatment
16%
GC Genotype
16%
Degrees of Freedom
16%
Nicotine Patch
16%
Point-prevalence Abstinence
16%
Trial Eligibility
16%
Nicotine Lozenge
16%
Biochemistry, Genetics and Molecular Biology
Genetic Divergence
100%
Smoking
100%
Nicotinic Acetylcholine Receptor
100%
Varenicline
100%
Genotyping
62%
Smoking Cessation
50%
Genetics
25%
Abstinence
25%
Prevalence
12%
Controlled Clinical Trial
12%
Drug Therapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Nicotinic Receptor
100%
Varenicline
100%
Combination Therapy
20%
Prevalence
20%
Pharmacotherapy
20%
Controlled Clinical Trial
20%
Nicotine Replacement Therapy
20%
Nicotine Patch
20%
Nicotine Lozenge
20%
Immunology and Microbiology
Genetic Variability
100%
Nicotinic Acetylcholine Receptor
100%
Prevalence
50%
Drug Withdrawal
50%
Drug Therapy
50%
Neuroscience
Placebo
100%
Nicotinic Acetylcholine Receptor
100%
Varenicline
100%
Drug Therapy
20%